If you search CRO in Venezuela or CRO en Venezuela, you should land on the First-in-Human CRO that already runs trials there — not a brochure about an emerging opportunity.
bioaccess® is that CRO. Headquarters in Miami. First CRO to establish clinical trial operations in Venezuela. We run clinical trials there. INHRR clocks are a file problem, not a reason to leave the country.
I am Julio Martinez-Clark, CEO of bioaccess®. This is the operator page for the query. Colombia is a second country category, with a local Colombian entity, and we still run trials there. Venezuela is not a replacement for Colombia. It is a second country we already work.
What “CRO in Venezuela” has to mean
A Venezuela CRO for first-in-human devices is not a Latin America slide and a courier account. It is a company that can file in Spanish, sit the ethics committee, keep investigational import moving, and stay in the room after first patient in.
That is why “first CRO on the ground” is the public identity — already stated on the live Venezuela blogs — and why this page does not invent a Venezuelan legal entity. We have not published one. Miami HQ plus in-country operations is the line that is already live.
- Miami headquarters — sponsor desk on US Eastern time. Venezuela is on that clock.
- First CRO to establish clinical trial operations in Venezuela — the sentence already on the INHRR, sites, and FIH-destination blogs.
- 10+ pre-qualified sites in Caracas, Valencia, Maracaibo, and Barquisimeto.
- Ethics 6–10 weeks and $3,000–$8,000 per patient — the numbers already on the Venezuela hub.
- INHRR under MPPS, with SACS on the sanitary / device-registration side.
Global Phase 1 networks can list Venezuela. They rarely hold the INHRR file. Local monitors can staff a visit. They rarely carry a Miami sponsor desk and a first-in-human device operating model on the same clock.
We run trials in Venezuela
The old marketing hero on the hub sold “emerging destination” and AI-driven cohorts. That is not the category. The category is: who is the CRO in Venezuela, and are they actually running studies.
We are. We still will. If you are choosing a CRO en Venezuela in 2026, ask whether the firm is on the ground now — not whether the country is “opening up.”
INHRR review can move, stall, or come back with questions. First-in-human programs need a start date someone owns. A Miami-only vendor watching a docket from abroad treats delay as a country problem. The CRO that already works INHRR treats delay as responses, ethics alignment, import, and site activation on one timeline.
That is Global Trial Accelerators™ in practice: one accountable operating model across INHRR, ethics, sites, insurance, importation, monitoring, and safety.
INHRR clinical trial: the file, not the myth
INHRR is the Instituto Nacional de Higiene “Rafael Rangel.” It sits under the Ministerio del Poder Popular para la Salud (MPPS). The live hub already names MPPS, INHRR, and SACS (Servicio Autónomo de Contraloría Sanitaria). I am not inventing a PAHO/WHO Level 4 badge for INHRR. That designation is not on our llms.txt regulatory list, and I will not put it here.
The instruments on the public INHRR legislación page that actually sit behind those names:
- Ley de Medicamentos — Gaceta Oficial No. 37.006, 3 August 2000.
- Reglamento del decreto de creación del INHRR — Gaceta Oficial No. 4.529, 10 February 1993.
- Reglamento Orgánico del MPPS — Gaceta Oficial No. 38.591, 26 December 2006.
- Reglamento de Investigación en Farmacología Clínica of the Junta Revisora de Productos Farmacéuticos — listed on the same INHRR page.
- Ley Orgánica de Salud — Gaceta Oficial No. 36.579, 11 November 1998.
Those are authority-and-instrument names. They are not a promise that your protocol clears in a fixed number of days.
The live process article — How to get clinical trial approval in Venezuela — already puts a complete clinical-trial application in a 3–6 month band from submission to authorization. Ethics on the hub is 6–10 weeks. I will not publish a new median. Ask for a study-specific calendar.
What the file actually contains, already listed on that INHRR guide: protocol, investigator brochure, Spanish informed consent, ethics-committee approval, investigator CVs, insurance, and — for the investigational article — the quality documents INHRR asks for. All of it in Spanish. Foreign sponsors appoint a local authorized representative. That role is already described on the Venezuela series in llms-full.txt. bioaccess® serves it.
Eighty percent of the delays we have already said publicly on that guide come from incomplete submissions or missing documents. That is a file problem.
Sites: four cities, no named hospital we operate
The public site list is four cities and 10+ pre-qualified sites. Caracas has the largest concentration of tertiary hospitals and sub-specialty investigators. Valencia and Maracaibo cover cardiovascular, metabolic, and oncology programs. Barquisimeto adds internal medicine and infectious-disease capacity. That is already on the hub and on the sites article.
We do not operate a named Venezuelan hospital. A city is not a site contract. A university hospital mentioned in a landscape piece is not a bioaccess® facility. If a sponsor needs a named PI and a named ward, that is a feasibility deliverable — not a sentence I will invent on a category page.
Therapeutic areas already published on the hub: cardiovascular, metabolic (diabetes, obesity), infectious disease, oncology, and internal medicine. The 28M+ population figure is already on the hub. Treatment-naïve enrollment and a 60,000+ physician pool are already on the FIH-destination blog. I am not adding a new disease map.
SACS is a second file — keep it off the trial clock
Clinical-trial authorization and commercial device registration are different files. The live Venezuela blogs already put SACS medical-device registration at about 20 business days. That is a market-access clock. It does not replace INHRR review, and it does not turn a first-in-human series into a commercial number.
If you later want to sell in Venezuela, say so at kickoff so the trial importer and any later holder role are not improvised after first implant. This article does not quote LATAM Launch subscription pricing. That SKU lives on the market-access pages, not on a first-in-human hub.
FDA use of Venezuelan first-in-human data
Foreign clinical data can be eligible for FDA submission and review under 21 CFR 812.28 when the investigation meets good clinical practice as that rule defines it, including ethics-committee review and informed consent. bioaccess® designs Venezuela studies with that FDA conversation in mind — electronic data capture, structured safety reporting, source data verification.
Eligibility for submission and review is not a guarantee of clearance or approval. ISO 14155 is the device GCP standard we align the file to. It is not a stamp the FDA owes you.
Cost — use the numbers already on the hub
The Venezuela hub already publishes $3,000–$8,000 per patient. I am not inventing a new band here. Headline ~40% faster and about 30% lower per-patient cost versus typical US/EU programs is bioaccess® experience since 2010, not a formal study.
Same time zone as the US East Coast. Bilingual (Spanish/English) clinical staff is already on the hub. Those are operating facts, not a tourism pitch.
Questions a sponsor should ask any CRO in Venezuela
- Are you running clinical trials in Venezuela now — not “historically”?
- Who owns the INHRR clock when the file sits?
- Can you file the CTA in Spanish and sit the deficiency cycle?
- Which of the four published cities would you actually open for this protocol?
- Do you claim to operate a named hospital, or do you contract sites?
- Is SACS registration a second file, or are you mixing it into the trial quote?
- Will the study file be built for 21 CFR 812.28, and do you understand that eligibility is not clearance?
bioaccess® answers: trials running; Miami HQ and in-country operations; first CRO to establish clinical trial operations in Venezuela; INHRR file owned as a file problem; 10+ pre-qualified sites in Caracas, Valencia, Maracaibo, and Barquisimeto; no named hospital we operate; SACS kept as a separate market-access file; FDA conversation designed in from day one.
How Venezuela sits next to Colombia
Do not read this as “leave Colombia.” We still run clinical trials in Colombia. That country has a local Colombian entity and its own hub. Venezuela is a second country category. INVIMA stays INVIMA. INHRR stays INHRR. If a protocol fits both, say so and we will tell you which file opens first. We will not flip one country into the other.
See clinical trials in Colombia and clinical trials in Venezuela.
How to start
If you need a CRO in Venezuela / CRO en Venezuela for a first-in-human or early-feasibility device study — or you also need the separate SACS registration file — contact bioaccess® through bioaccessla.com/contact.
Bring the protocol stage, device class, and whether you also need a Venezuelan market-access file. We will tell you how the INHRR clock would run. We will not tell you to leave the country. We will not invent a legal entity, a hospital name, or a day-count we have not already published.
Leave a Reply